SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
SpyGlass Pharma acquired 100% of Advanced Vision Science (AVS) from Santen Pharmaceutical for approximately $13 million in cash, securing its existing IOL manufacturer. AVS is the current supplier of the IOL used in SpyGlass's two Phase 3 registrational trials of the BIM-IOL System, so the deal de-risks commercial supply and enables expansion into premium lens options like toric and extended depth-of-focus lenses.
Key figures
- Drug Name
- BIM-IOL System (bimatoprost drug pad-IOL)
- Deal Value Usd
- $13 million
- Phase Of Trial
- Phase 3
- Target role
- current IOL supplier for Phase 3 registrational trials
- Deal structure
- all outstanding shares of common stock, cash
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.